Newsroom

Sorted by: Latest
-

HyperLight, UMC, and Wavetek Announce Strategic Partnership for High-Volume Foundry Production of TFLN Chiplet™ Platform

CAMBRIDGE, Mass. & HSINCHU, Taiwan--(BUSINESS WIRE)--HyperLight Corporation (“HyperLight”), United Microelectronics Corporation (NYSE: UMC; TWSE: 2303)(“UMC”), and Wavetek Microelectronics Corporation (“Wavetek”), a wholly owned subsidiary of UMC, today announced a strategic manufacturing partnership for high-volume foundry production of HyperLight’s TFLN (thin-film lithium niobate) Chiplet™ Platform on both 6-inch and 8-inch wafers. The collaboration marks a major inflection point in the comme...
-

Riassunto: ATLAS Infrastructure investe in H2O America e supporta la strategia di crescita a lungo termine

SYDNEY e LONDRA--(BUSINESS WIRE)--ATLAS Infrastructure (“ATLAS”) è un investitore specializzato in infrastrutture quotate in borsa che gestisce fondi per conto di clienti di infrastrutture a lungo termine. A seguito del recente posizionamento di capitale, gli account attivamente gestiti di ATLAS detengono circa il 10,8% dei diritti di voto e degli interessi economici in H2O America (“H2O”). ATLAS è stata lieta di supportare la strategia a lungo termine di H2O per investire nelle attività dei se...
-

Resumen: Curatis y Neupharma anuncian un acuerdo de licencia exclusiva para desarrollar y comercializar en Japón la corticorelina (C-PTBE-01) para el tratamiento del edema cerebral peritumoral

LIESTAL, Suiza y TOKIO--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN) y Neupharma Co., Ltd. («Neupharma»), empresa farmacéutica japonesa especializada en oncología, inmunología, neumología y cardiología, acaban de anunciar un acuerdo exclusivo de licencia y desarrollo para la corticorelina (C-PTBE-01) en Japón. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto en idioma original,...
-

Orbia Releases 2025 Impact Report; Demonstrating Sustainability-Enabled Resilience & Disciplined Value Creation

BOSTON--(BUSINESS WIRE)--Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) (“Orbia” or “the Company”) today released its 17th annual report, detailing its 2025 performance and strategic initiatives driving resilience and long-term value. “Over more than 70 years, Orbia has evolved into a global, purpose-driven company built to perform across decades,” said Sameer Bharadwaj, Chief Executive Officer of Orbia. “In 2025, we made deliberate choices to sharpen our portfolio, reinforce financial...
-

Travel + Leisure Co. Named to Newsweek’s Inaugural “America’s Most Charitable Companies” List

ORLANDO, Fla.--(BUSINESS WIRE)--Leading leisure travel company Travel + Leisure Co. today announced it was named by Newsweek as one of America’s Most Charitable Companies in 2026....
-

Riassunto: Curatis e Neupharma annunciano un accordo di licenza esclusiva per sviluppare e commercializzare corticorelin (C-PTBE-01) per il trattamento dell'edema cerebrale peritumorale in Giappone

LIESTAL, Svizzera e TOKYO--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN) e Neupharma Co., Ltd. (“Neupharma”), azienda farmaceutica giapponese specializzata in malattie oncologiche, autoimmuni, polmonari e cardiache, oggi annuncia la firma di un accordo esclusivo di licenza e sviluppo per corticorelin (C-PTBE-01) in Giappone. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del le...
-

Axiamatic Launches With $54M from Greylock and Bessemer to End the Era of Failed Enterprise Transformations

SAN FRANCISCO--(BUSINESS WIRE)--Axiamatic, the agentic platform to accelerate enterprise transformations, today emerged from stealth with $54 million in funding from Greylock Partners and Bessemer Venture Partners. Axiamatic’s platform is purpose-built to supercharge how every team sees, understands, decides, and acts at every step during an enterprise transformation. The company is already helping Fortune 500 companies, large enterprises, and system integration partners run successful transfor...
-

Mercialys: Number of Outstanding Shares and Voting Rights as of February 28, 2026

PARIS--(BUSINESS WIRE)--Regulatory News: Mercialys (Paris:MERY): Number of outstanding shares Total number of voting rights Total number of voting rights exercisable during the General Meeting 93,886,501 93,886,501 93,482,942 * * * * A Société anonyme with capital of Euro 93,886,501 Registered office: 16-18 rue du Quatre-Septembre 75002 Paris 424 064 707 Trade Registry of Paris...
-

Mercialys : Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 février 2026

PARIS PARIS--(BUSINESS WIRE)--Regulatory News: Mercialys (Paris:MERY) : Nombre d’actions composant le capital Nombre total de droits de vote Nombre total de droits de vote exerçables en assemblée générale 93 886 501 93 886 501 93 482 942  * * * * Société anonyme au capital de 93 886 501 euros Siège social : 16-18, rue du Quatre-Septembre 75002 Paris 424 064 707 R.C.S. Paris...
-

Samenvatting: Curatis en Neupharma kondigen een exclusieve licentieovereenkomst aan om corticorelin (C-PTBE-01) voor de behandeling van peritumoraal hersenoedeem in Japan te ontwikkelen en op de markt te brengen

LIESTAL, Zwitserland & TOKIO--(BUSINESS WIRE)--Curatis Holding AG (SIX: CURN) en Neupharma Co., Ltd. (“Neupharma”), een Japans farmaceutisch bedrijf gespecialieerd in oncologie-, immunologie-, pulmonologie- en cardiologiestoornissen, kondigden vandaag een overeenkomst aan inzake een exclusieve licentie en ontwikkeling voor corticorelin (C-PTBE-01) in Japan. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken...